Metformin therapy modifies corneal neuroimmune abnormalities in people with type 2 diabetes
Authors' conclusion
Metformin treatment is associated with superior corneal nerve parameters and neuroimmune tone in the corneal sub-basal nerve plexus. This study provides further evidence that metformin may be neuroprotective in diabetic peripheral neuropathy.
Study context
- Population
- People with T2D; clinical assessment, corneal confocal microscopy and nerve conduction studies
- Participants
- 36 / 36 / 25
- Exposure
- Metformin therapy vs no metformin therapy in T2D
- Metforminn = 36
- Non-metforminn = 36reference
- Healthy controlsn = 25
- Outcome
- Corneal sub-basal nerve plexus as a peripheral neuropathy outcome measure
Methodological detailsmatched for age, sex, diabetes duration, BMI, eGFR, HbA1c, other oral glucose-lowering agents and metabolic syndrome therapies, Medical record data over previous 20 years analysed for prior and current metformin use
- Matched for age, sex, diabetes duration, BMI, eGFR, HbA1c, other oral glucose-lowering agents and metabolic syndrome therapies
- Medical record data over previous 20 years analysed for prior and current metformin use
Main finding
As reported in the abstract
Corneal nerve parameters
- Metformin vs Non-metformin: P = 0.020
- Metformin vs Non-metformin: P = 0.020
- Metformin vs Non-metformin: P = 0.003
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Inferior whorl dendritic cell densityMetformin vs Non-metformin · significantly lower with metformin | P = 0.043 |
Original publication
Metformin therapy modifies corneal neuroimmune abnormalities in people with type 2 diabetes. Diabetologia. Published 7 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →